Considerable progress has been made in the past several years in the scientific
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …

Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival
by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical …

We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study
Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by …

Most patients with acute myeloid leukemia (AML) relapse eventually because of the inability
to effectively eliminate leukemia stem cells (LSCs), prompting the search of new therapies to …

Simple Summary It is urgent to identify new biomarkers for diagnosis, prognostication, and
therapeutic targets of acute myeloid leukemia (AML) so as to develop more effective …

Background Although the development of BCR:: ABL1 tyrosine kinase inhibitors (TKIs)
rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug …

Acute myeloid leukemia (AML) is initiated and sustained by a hierarchy of leukemia stem
cells (LSCs), and elimination of this cell population is required for curative therapies. Here …

The aim of this study was to characterize the mutational landscape of patients with FLT3-
mutated acute myeloid leukemia (AML) treated within the randomized CALGB …

Menin inhibitors constitute a novel class of agents targeting the underlying biology of
nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) …

Mitochondrial metabolism recently emerged as a critical dependency in acute myeloid
leukemia (AML). The shape of mitochondria is tightly regulated by dynamin GTPase …